Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-1607-2023Class II

Beckman Coulter Bicarbonate, REF: OSR6237, 4x50 mL

Siemens Healthcare Diagnostics Inc. / initiated 2023-04-05 / Open, Classified / root cause: manufacturing process

Beckman Coulter Inc. began a recall of Beckman Coulter Bicarbonate, REF: OSR6237, 4x50 mL on . FDA classified it as Class II and gives the reason as "There is a potential for a decrease in calibration ODs for Bicarbonate reagent which could result in calibration failures and/or quality control failures". As of , the recall status on record is Open, Classified, and MDM tags the root cause as manufacturing process.

Recall record

Recall number
Z-1607-2023
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
Siemens Healthcare Diagnostics Inc.
Product
Beckman Coulter Bicarbonate, REF: OSR6237, 4x50 mL
Product code
KHS Enzymatic, Carbon-Dioxide
Reason for recall
There is a potential for a decrease in calibration ODs for Bicarbonate reagent which could result in calibration failures and/or quality control failures.
Root cause tag
manufacturing process
FDA root cause
Under Investigation by firm
Action
On April 5, 2023, Beckman Coulter (BEC) issued a "URGENT MEDICAL DEVICE RECALL" Notification via mail and/or E-Mail. In addition, to informing consignees about the recalled product, BEC asked consignees to take the following actions: 1. Safely dispose of the Bicarbonate lot numbers that are specifically described in Table A. 2. If replacement or re-imbursement of the above lots is required, customers are directed to contact their local Beckman Coulter representative for replacement and re-imbursement. 3. Customers are advised to implement the adjusted Calibration OD range using the instructions within the customer letter to avoid generation of elevated results for all other Bicarbonate lots. 4. Retrospective review of patient data is not required due to the remote possibility of generating falsely elevated, clinically impactful results which could cause a change in treatment. Please share the content of this letter with your laboratory and/or medical director regarding the need to review previous patient test results. 4. Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forward any of the affected products(s) listed above to another laboratory, please provide them a copy of the letter. 5. Please respond within 10 days in one of the following ways: - Electronically, you received this communication via email. - Manually, complete and return the enclosed Response Form. 6. If you have any questions, please call 1-800-854-3633
Quantity in commerce
48,633 units in total
Distribution
Worldwide Distribution: US (nationwide): AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WV, WY, Guam, & Puerto Rico and OUS (foreign) countries of: Brazil ,Canada, Mexico, Panama, Taiwan,
Product codes and lots
All Lots: UDI-GI: 15099590010348

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-1607-2023
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-1606-2023Class IIOngoingVoluntary: Firm initiated
Z-1607-2023Class IIOngoingVoluntary: Firm initiated
Z-1608-2023Class IIOngoingVoluntary: Firm initiated